Biomarker for breast cancer

The present invention relates to a marker to guide breast cancer treatment available. The present invention relates to a diagnostic kit and / or diagnosis of breast cancer which comprises the monoclonal antibody with the anti-LAT1 monoclonal. Of the oil pipes in neoplastic lesions, malignant a related non-invasive cancer as compared to Ryu Dujong-positive in related, the monoclonal antibodies useful in that LAT1 is that significantly high expression, with the anti-LAT1 monoclonal antibody to the diagnosis of both lesions. Also, from which most of the molecular target markers of conventional breast cancer and either side of the ER, PgR, HER2 negative and triple does not have appropriate molecular target therapy negative invasive cancer that was expressing high levels of LAT1, LAT1 is a new molecular target for breast cancer and a marker, the present immunohistochemical methods with the development of the diagnosis should LAT1 expression, molecular targeted therapy targeting LAT1 method is effective.